Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.60 |
| ▸ | RAB9A | P51151 | 8/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MIF | P14174 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | GLS | O94925 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8143171 | 0.92 | KDM4E (0.64) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL27821589 | 0.88 | RAB9A (0.58) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL2421423 | 0.84 | KDM4E (0.75) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL13499907 | 0.83 | KMT2A (0.61) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL15515850 | 0.83 | KDM4E (0.60) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL31030144 | 0.82 | ALDH1A1 (0.54) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL8142656 | 0.82 | NPC1 (0.52) | NPC1RAB9AKMT2AMEN1RXFP1 | |
| SCHEMBL5332558 | 0.82 | ALDH1A1 (0.64) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL9156058 | 0.82 | ALDH1A1 (0.60) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL3828303 | 0.80 | NPC1 (0.71) | NPC1RAB9AKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054876-A1 | 1,3,4-THIADIAZOLES DERIVATIVES AS KYN-OH INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 2000-11-29 | — | — | EP | claimed |
| WO-1999028309-A1 | 1,3,4-THIADIAZOLES DERIVATIVES AS KYN-OH INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-06-10 | — | — | WO | claimed |
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | ASTRAZENECA AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | ASTRAZENECA AB (SE) | 2014-02-06 | — | — | US | disclosed |
| CN-101128427-B | Heterocyclic compounds as ccr2b antagonists | ASTRAZENECA AB | 2013-03-27 | — | — | CN | disclosed |
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-7906645-B2 | Heterocyclic compounds as ccr2b antagonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-7906645-B2 | Heterocyclic compounds as ccr2b antagonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| EP-1129089-A4 | SPIRO-INDOLINES AS Y5 RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6495559-B2 | FOR THERAPY OF OBESITY | MERCK & CO., INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020058813-A1 | Spiro-indolines as Y5 receptor antagonists | MSD K.K. (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6313298-B1 | OBESITY, DIETETICS; NEUROPEPTIDE Y ANTAGONISTS | MERCK & CO., INC. | 2001-11-06 | — | — | US | disclosed |
| EP-1129089-A1 | SPIRO-INDOLINES AS Y5 RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2001-09-05 | — | — | EP | disclosed |
| US-6191160-B1 | DIETETICS | MERCK & CO., INC. | 2001-02-20 | — | — | US | disclosed |
| EP-1054876-A1 | 1,3,4-THIADIAZOLES DERIVATIVES AS KYN-OH INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000027845-A1 | SPIRO-INDOLINES AS Y5 RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| WO-1999028309-A1 | 1,3,4-THIADIAZOLES DERIVATIVES AS KYN-OH INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | CCR2, CCR3, CXCR2 | NPC1 1260/4885RAB9A 3914/4885KMT2A 3450/4885 |
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | CCR2, CCR3, CXCR2 | NPC1 1658/4885RAB9A 4068/4885KMT2A 3297/4885 |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | CCR2, CCR3, CXCR2 | NPC1 1577/4885RAB9A 4032/4885KMT2A 3262/4885 |
| US-20020058813-A1 | Spiro-indolines as Y5 receptor antagonists | NPY5R, NPY1R, NPY2R | NPC1 3050/4885RAB9A 2439/4885KMT2A 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.